Suppressing DNMT1 activity with a DNMT inhibitor resulted in the amelioration of obesity-induced glucose intolerance and insulin resistance in an adiponectin-dependent manner. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.